Arkolith/Insider Trading/VKTX/Form 4

Zante Greg

Chief Financial OfficerViking Therapeutics, Inc. (VKTX) · full profile →Form 4 · filed Jan 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.9M
Net Open-Market Flow
-$1.9M
Transactions
7
6 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Sell(S)14K$33.38$464K202K
Jan 5, 2026Sell(S)32K$32.30$1.0M216K
Jan 5, 2026Sell(S)10K$34.24$353K191K
Jan 5, 2026Sell(S)2K$32.09$48K190K
Jan 2, 2026Grant(A)32K—$0248K
Jan 2, 2026Grant(A)41K—$0215K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Grant(A)91K—$091K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-003116) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML